New labeled indication targets facial structure correction and premium pricing opportunity.
Galderma has secured FDA approval for Restylane Contour for temple hollowing—a structural correction indication that addresses age-related volume loss in the temporal region. Restylane Contour is a thicker-gel HA formulation designed for deeper placement and structural support, distinct from Restylane Refyne (dynamic expression lines) and Restylane Lyft (cheek/hand volume).
Temple hollowing is a high-visibility sign of aging and a common patient concern, yet most practices have relied on off-label use of thicker fillers or Sculptra (PLLA biostimulator) for this zone. A cleared indication removes prescriber liability and creates a labeled, reimbursable pathway—though most aesthetic work remains cash-pay. The temple is a premium anatomical zone with strong patient demand and limited competitive pressure from other fillers.
Temple hollowing approval removes off-label prescribing and opens a premium structural-correction indication.
For practices, this approval reinforces Galderma's strategy to expand Restylane's clinical footprint across facial anatomy. Expect corresponding rebate incentives through Aspire to drive adoption alongside existing Restylane lines. The indication also positions Restylane Contour as a direct alternative to Sculptra for structural correction, potentially shifting economics depending on per-unit pricing and rebate structure.
Source: original report ↗
Frequently asked questions
Is Restylane Contour FDA approved for temple hollowing?
Yes, Galderma recently secured FDA approval for Restylane Contour specifically for temple hollowing—a structural correction indication for age-related volume loss in the temporal region. This labeled indication removes prescriber liability and creates a reimbursable pathway, though most aesthetic treatments remain cash-pay.
What's the difference between Restylane Contour, Refyne, and Lyft?
Restylane Contour is a thicker-gel HA formulation designed for deeper placement and structural support in areas like temples. Restylane Refyne targets dynamic expression lines, while Restylane Lyft addresses cheek and hand volume. Each formulation is optimized for different anatomical zones and aging concerns.
Can you use Restylane Contour off-label for temple hollowing before the FDA approval?
While practices could previously use thicker fillers or Sculptra off-label for temples, the new FDA-cleared indication removes prescriber liability and provides a labeled, reimbursable pathway. The approval gives practices a safer, compliant option specifically designed for this zone.
Is Restylane Contour a competitor to Sculptra for temple treatment?
Yes, Restylane Contour now positions as a direct alternative to Sculptra (PLLA biostimulator) for structural correction in the temple. The competitive dynamics will depend on per-unit pricing, rebate structure through Aspire, and patient preference for immediate HA results versus gradual biostimulation.
Why is temple hollowing a premium treatment opportunity for med spas?
Temple hollowing is a high-visibility sign of aging and a common patient concern with limited competitive pressure from other fillers. The temple is considered a premium anatomical zone with strong patient demand, making it an attractive revenue opportunity for practices offering structural correction services.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
